We are Salvia BioElectronics
Our mission is to give people with migraine a better life
Salvia BioElectronics is a medical device company pioneering neuromodulation therapies for migraine. Salvia's unique, paper-thin implant is designed to reduce the frequency and intensity of migraine attacks by delivering gentle electrical pulses to the nerves associated with the condition. The company is currently in the clinical stage of development. In addition, Salvia is considering potential opportunities the device creates for the treatment of cluster headache and other neurological disorders. Salvia has received the Breakthrough Device Designation from the United States Food and Drug Administration (FDA), which facilitates expedited market access for devices that treat life-threatening or irreversibly debilitating conditions.
Our solution
.jpg)
A paper-thin implant for people with severe migraine
Salvia BioElectronics' migraine therapy consists of two ultra-thin implants: one placed just beneath the skin of the forehead and another just beneath the skin at the back of the head. Patients receive an external, wearable device that allows them to activate the therapy with the press of a button.
Salvia’s device is not yet approved for commercial use. We make no claims about safety or effectiveness.
Neuromodulation therapy for migraine
Salvia’s unique implant is designed to reduce the frequency and intensity of migraine attacks by delivering gentle electrical pulses to the nerves associated with the condition. This technology, known as neuromodulation, has been successfully used for decades in the treatment of other neurological disorders, such as Parkinson’s disease and epilepsy.
Electrical signals within the nervous system control how our body moves, feels and functions. In migraine, these signals can be disrupted. Neuromodulation may help correct this and restore balance.
"We are committed to providing people with severe migraine a new treatment option through their neurologist," says Dr. Wim Pollet, Medical Director at Salvia BioElectronics.
Our mission is to help people with migraine reclaim control over their lives.
- Yilong Zheng, Christopher Weiyang Liu, Diana Xin Hui Chan, Damian Wen Kai Ong, Justin Rui Xin Ker, Wai Hoe Ng, Kai Rui Wan, Neurostimulation for Chronic Pain: A Systematic Review of High-Quality Randomized Controlled Trials With Long-Term Follow-Up, Neuromodulation: Technology at the Neural Interface, Volume 26, Issue 7, 2023, Pages 1276-1294, ISSN 1094-7159
- M. D. Johnson et al., "Neuromodulation for Brain Disorders: Challenges and Opportunities," in IEEE Transactions on Biomedical Engineering, vol. 60, no. 3, pp. 610-624, March 2013, doi: 10.1109/TBME.2013.2244890
MySalvia device and app intend to empower patients to take control
Patients can manage their own migraine treatment with a wearable, external device called the "MySalvia device". This device interfaces with the implant to activate the neuromodulation therapy, tailored to the patient's needs.
We are also developing the MySalvia app, which, in the future, will allow patients to monitor their progress and access personalized migraine treatments.
Why the name Salvia?
The name Salvia comes from the Latin word "salvere," meaning to be in good health. Throughout history, the Salvia plant has been valued for its extraordinary medicinal properties, known for its ability to relieve pain, alleviate headaches, and even treat mental disorders. At Salvia, we believe everyone deserves good health, and that's why we are passionately committed to improving the lives of people with migraine.
How it started…
Salvia was founded on March 3, 2017 by Hubert Martens, Daniel Schobben and Wim Pollet. Starting with nothing more than innovative ideas and a blank whiteboard, the founders (with extensive backgrounds in medical technology and neuromodulation) began their journey by understanding the needs of medical professionals and patients, building a team and conceptualizing the first shapes, characteristics and functionalities of a neuromodulation solution for people with migraine.
It is not “just a headache”
Migraine affects more than one billion people worldwide each year and is the leading cause of disability in people under 50. Cluster headache, which causes excruciating pain behind the eye, is a rare neurological disorder affecting 1 in 1000 people. Read more about both conditions we address with our bioelectronic solution.